A longitudinal study of prediagnostic metabolic biomarkers and the risk of molecular subtypes of colorectal cancer

• Published in: Scientific reports 2020-03, Vol.10 (1), p.5336-5336, Article 5336
• Main Authors: Myte, Robin, Harlid, Sophia, Sundkvist, Anneli, Gylling, Björn, Häggström, Jenny, Zingmark, Carl, Burström, Anna Löfgren, Palmqvist, Richard, Guelpen, Bethany Van
• Format: Article
• Language: English
• Subjects: 45/23; 631/67/2324; 692/4028/67/2195; 82; 82/51; Adiponectin; Adiponectin - blood; Adult; Aged; Biomarkers; Biomarkers - blood; Body mass index; Body size; C-Peptide - blood; Case-Control Studies; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - diagnosis; Colorectal Neoplasms - genetics; Colorectal Neoplasms - metabolism; Female; Humanities and Social Sciences; Humans; Insulin; Insulin - blood; Leptin; Leptin - blood; Longitudinal Studies; Male; Microsatellite Instability; Middle Aged; multidisciplinary; Mutation; Peptides; Proto-Oncogene Proteins B-raf - genetics; Proto-Oncogene Proteins p21(ras) - genetics; Regression analysis; Risk Factors; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-62129-1

Body fatness increases the risk of colorectal cancer (CRC). Insulin resistance and altered adipokines are potential mechanisms, but previous biomarker studies have been inconsistent. Intertumoral heterogeneity might provide an explanation. We investigated insulin, C-peptide, adiponectin, and leptin in relation to CRC molecular subtypes using a nested case-control design (1010 cases, 1010 matched controls, median 12.3 years from baseline to CRC diagnosis) from the population-based Northern Sweden Health and Disease Study. Repeated samples were available from 518 participants. Risks of CRC and subtypes, defined by tumor BRAF and KRAS mutations and microsatellite instability (MSI) status, were estimated using conditional logistic regression and linear mixed models. Higher C-peptide and lower adiponectin were associated with increased CRC risk (odds ratios per standard deviation increase (95% CI): 1.11 (1.01, 1.23) and 0.91 (0.83, 1.00), respectively), though weakened when adjusted for body mass index. Insulin and leptin were not associated with CRC risk. Within-individual time trajectories were similar in cases and controls, and no subtype-specific relationships were identified (all P heterogeneity > 0.1). Adiponectin was weakly inversely associated with the risk of KRAS -mutated (P = 0.08) but not BRAF -mutated or KRAS/BRAF -wildtype CRC, consistent with the one previous study. These findings contribute to an increased understanding of the complex role of body size in CRC.